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Previous research in patients with schizophrenia in European and USA population groups
has demonstrated a high prevalence of metabolic syndrome and disease progression
(~35%–40%) and increased risk for cardiovascular disease and long-term mortality.
Limited research has determined the prevalence of existing cardiometabolic risk factors
at onset of a first episode psychosis. This cross-sectional study presents a clinical
overview of the cardiometabolic risk profile in young people with first episode psychosis
in the UK. Forty-six participants (72% male) clinically diagnosed with first episode
psychosis (n = 25), schizophrenia (n = 13), bipolar disorder (n = 4), unspecified non-
organic psychosis (n = 2) or acute psychotic episode (n = 2) with < 6 months Duration of
Untreated Psychosis (DUP; mean 33.4 ± 37.2 days) were assessed for anthropometric,
health risk behaviors and clinical measurements including resting heart rate, blood
pressure, blood lipids, glycated hemoglobin, and prolactin. Overall, participants (aged
18–37 years) had a high prevalence of cardiometabolic risk factors due to: elevated values
for BMI (73%) and abdominal adiposity (50%), blood pressure (47% prehypertensive;
23% hypertensive), resting heart rate (43%); hypercholesterolemia (32%); suboptimal
HDL-C levels (36%); and hypertriglyceridemia (40%). Participants also self-reported poor
health risk habits including smoking (55%), alcohol use (39%), substance use (18%), poor
diet (52%), and sedentary behavior (29%). Young people with psychosis are at increased
risk for cardiometabolic disorders due to elevated clinical markers and health risk
behaviors. Physical health interventions (including health behavior advice) are needed
early in the treatment process to address this increased risk for cardiometabolic disorders
in individuals recently diagnosed with psychosis.
Keywords: first episode psychosis, cardiometabolic risk, duration of untreated psychosis, lifestyle behaviors,
metabolic syndrome, serious mental illnessAbbreviations: EIP, Early Intervention in Psychosis; FEP, first episode psychosis; NHS, National Health Service; PA, physical
activity; SMI, serious mental illness; T2DM, type 2 diabetes mellitus; MetS, metabolic syndrome.
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Research in people with schizophrenia, bipolar disorder and
psychosis in USA and Europe has demonstrated a high prevalence
of metabolic syndrome (MetS) and disease progression (~35%–40%)
contributing to an increased risk for cardiometabolic disorders and
long-term mortality (1–4). Evidence suggests increased risk of
cardiovascular mortality is ~2.5 times higher in individuals with
psychosis compared to age-matched counterparts (5–8). Patients
with serious mental illness (SMI) have an increased prevalence of
developing obesity, hyperglycaemia, dyslipidaemia, hypertension,
hyperprolactinemia and MetS (1, 9–12). These individuals are also
four to five times more likely to be smokers (13) with elevated rates
of obesity up to twice those of the general population (14).
Individuals with a first episode psychosis (FEP) are particularly
susceptible to rapid and pronounced weight gain (15).
Antipsychotic medications, particularly obesogenic agents such
as Olanzapine and Clozapine, can exacerbate weight gain, and
increase levels of blood glucose and fasting triglycerides (16–18).
However, Zhang et al. (19) showed glucose disturbances in first-
episode drug-naïve schizophrenia patients, suggesting that
medication is not the sole contributor leading to these adverse
outcomes but may combine with underlying psychopathology
factors, notably, impaired glucose homeostasis (20), glucose
tolerance, and insulin resistance (21). Stahl et al. (22) reported
that even without weight gain, increased fasting triglycerides
strongly correlates with development of insulin resistance. This is
consistent with recent research demonstrating higher incidences of
type 2 diabetes mellitus (T2DM) in individuals taking Olanzapine,
Clozapine, and some other antipsychotic medications (23, 24). In
comparison, the general population has benefited from improved
cardiovascular health due to primary and secondary prevention,
while SMI patients remain at increased risk due to less opportunity
for cardiovascular risk screening, less access to general health care,
sedentary behavior, weight gain, and poor diet (25).
Research in the USA and UK has demonstrated a high prevalence
of metabolic syndrome (MetS) in schizophrenia patients (~13%–
57%) (1, 10) which presents an increased risk for cardiovascular
disease (CVD), impaired daily functioning and long-term mortality
(18–26). There is limited research in European populations
comparing the metabolic risk profile of individuals with early
psychosis compared to age-matched general population
counterparts (27, 28). In a UK context, there have been two studies
that have investigated cardiometabolic risk in first episode patients.
The first paper by Ryan et al. (29) examined the prevalence of fasting
glucose tolerance in hospitalized first episode patients with
schizophrenia. The second paper was a large scale, prospective
cohort study of an ethnically diverse group of patients with FEP,
aged 16–65 years, within 6 months of their first presentation with
psychosis (30) whose cardiometabolic outcomes were monitored
over a 12-month period. Neither study specified the length of time
from the onset of psychotic illness to initiation of antipsychotic
treatment of study participants, known as the duration of untreated
psychosis (DUP). A measure of DUP is needed to control for the
influence of duration of psychotic illness and the development of
illness-related health risk habits such as poor diet, decreased physical
activity, and smoking on specific cardiometabolic measures,Frontiers in Endocrinology | www.frontiersin.org 2particularly glucose homeostasis (31) and risk for MetS (32). This
is the first UK study to look at cardiometabolic risk in association
with health risk behaviors in an unselected, young, early psychosis
cohort, within 3 months of psychosis onset. The aim of this cross-
sectional study is to present a clinical overview of the cardiometabolic
risk prevalence for individuals with FEP with a short DUP on
presentation to a UK Early Intervention in Psychosis (EIP) service.MATERIALS AND METHODS
Patients and Diagnoses
Clinical data collection for FEP patients was conducted in the
first six weeks following acceptance onto caseload of two UK
Early Intervention in Psychosis (EIP) teams, between June 2014
to June 2015. The EIP service remit is to work with young people
(14–35 years) presenting with FEP or bipolar disorder. Forty-six
participants (~68% of annual clinical intake) clinically diagnosed
with a provisional diagnosis of FEP (33), schizophrenia, bipolar
disorder, acute psychotic episode, and unspecified non-organic
psychosis with a DUP < 6 months were included in the study (see
Table 1). Clinical diagnosis was determined by an independent







Age (y) 24.5 (4.4) 24.0 (3.9) 25.7 (5.4)
Duration Since Onset
0–3 mo 40 (87.0%) 29 (87.2%) 11 (84.6%)
3–6 mo 6 (13%) 4 (12.1%) 2 (15.4%)
Ethnicity (%)
White 40 (87.0%) 28 (84.8%) 12 (92.3%)
Asian 4 (8.8%) 4 (12.1%) 0
Chinese 1 (2.2%) 0 1 (7.7%)
Undeclared 1 (2.2%) 1 (3.0%) 0
Primary SCID Diagnosis
FEPa 25 (54.3%) 19 (57.6%) 6 (46.2%)
Schizophrenia 13 (28.3%) 10 (30.3%) 3 (23.1%)
Bipolar 4 (8.7%) 1 (3.0%) 3 (23.1%)
Acute psychotic episode 2 (4.3%) 2 (6.1%) 0
Non-organic 1 (2.2%) 0 1 (7.7%)
Other 1 (2.2%) 1 (3.0%) 0
Antipsychotic Treatment (%)
No medication 9 (17.8%) 7 (21.1%) 2 (15.4%)
Aripiprazole 4 (8.9%) 4 (12.1%) 0
Clozapine 3 (6.7%) 3 (9.1%) 0
Olanzapine 13 (28.9%) 9 (27.3%) 4 (30.8%)
Paliperidone 1 (2.2%) 1 (3.1%) 0
Quetiapine 13 (28.9%) 7 (21.2%) 6 (46.2%)
Risperidone 2 (4.4%) 1 (3.0%) 1 (7.7%)
Other 1 (2.2%) 1 (3.1%) 0
Antidepressant Treatment (%)
No medication 31 (67.4%) 25 (75.8%) 6 (46.2%)
Citalopram 1 (2.2%) 1 (3.0%) 0
Sertraline 2 (4.3%) 2 (6.1%) 0
Venlafaxine 4 (8.7%) 2 (6.1%) 2 (15.4%)
Fluoxetine 2 (4.3%) 0 2 (15.4%)
Other 5 (10.9%) 3 (9.1%) 3 (23.1%)November 2020 | Volume 11 | Artaprovisional diagnosis of First Episode of Psychosis (FEP) (33).icle 564240
Smith et al. Cardiometabolic Risk in FEP PatientsInternational Classification of Diseases (ICD)-10 (34) criteria for
a psychotic disorder.
Participation eligibility was determined by an EIP mental
health nurse. Exclusion criteria included: patient too unwell or
declined to participate in a physical health assessment, early
discharge, or where care involvement was limited (i.e., studying/
working elsewhere). The NHS Health Research Authority
decision making process classified this project as a clinical
service evaluation. Ethical approval was obtained from the
University Research Ethics Committee (REC approval
no.:UWEC2014JS1).
Clinical Assessment
Upon caseload acceptance, participants had a routine physical
health assessment conducted by a mental health nurse. Clinical
markers included DUP, medical history, medications and health
risk behaviors. Physical health markers were assessed against
World Health Organization (35), International Diabetes
Federation (IDF) criteria for MetS (36), and Lester UK
Adaptation (37) criteria to determine risk levels for
cardiovascular and metabolic disorders. Measures included:
body mass index (BMI), waist circumference, resting heart rate
and blood pressure, glycated hemoglobin (HbA1c), fasting
plasma glucose (FPG), and blood lipids. Blood lipids included
measures of total cholesterol, low-density lipoprotein (LDL-C),
high-density lipoprotein (HDL-C), and triglycerides. Prolactin
levels were assessed using criteria published in Taylor et al. (38).
Abdominal adiposity was assessed using waist circumference
where measurements were made at the approximate midpoint
between the lower margin of the last palpable rib and the top of
the iliac crest (35). Blood tests to determine HbA1c and/or FPG,
blood lipids and prolactin were requested by the patient’s general
practitioners and conducted by NHS pathology departments. All
blood data were collected from electronic patient records.
Health risk behaviors were assessed using self-reported measures
for diet [eating > 5 fruit/vegetables per day; equivalent to 400 g a day
based on 80 g portions; (39)], tobacco use (current smoker or within
last 6 months), alcohol use [Alcohol Use Disorders Identification
Test; (40)], substance use (yes/no response), and PA levels [Exercise
Vital Sign (EVS); (41)]. Sedentary behaviors were determined as
engaging in PA less than 90 min of moderate PA per week (42).Data Analysis
We conducted a cross-sectional analysis of baseline clinical
assessment data. Frequency analyses were conducted to determine
demographic data, and prevalence of cardiometabolic and health
risk factors (SPSS v. 25.0). Independent sample t-tests were
performed on scaled data and Mann-Whitney U tests were
performed on categorical data to determine sex differences across
outcome measures. A binary logistic regression analysis was
performed to ascertain impact of health risk behaviors, DUP and
antipsychotic medications on risk of dyslipidemia, MetS, and
hypertension. Scaled data were presented as mean (SD).
Categorical data was presented as frequency and/or percent of the
total population. Alpha level was set at p < 0.05.Frontiers in Endocrinology | www.frontiersin.org 3RESULTS
Demographic, Illness, and Treatment
Characteristics
Participants included 46 patients (72% males; 28% females),
primarily White British, clinically diagnosed with FEP with a
DUP < 3 months (mean DUP 33.4 ± 37.2 days); 63% had a
DUP < 1 month (see Table 1). Physical health assessments were
conducted in the first six weeks following acceptance onto the
EIP team caseload. At assessment, 82% were in receipt of
antipsychotic medication, 33% were on antidepressant
medication, and no patients were prescribed mood stabilizers.
Forty-one participants (89%) completed all physical
measurements; only 20 participants (44%) completed all blood
profile assessments. Reasons for incomplete assessments
included: differences in blood tests requested by general
practitioner (LDL and triglycerides were not ordered in one
service), refusal to give blood and/or participate in sensitive
physical measurements (e.g., waist circumference), declined
based on religious concerns, repeat non-attendance for
screening appointments, or no reason given.
Cardiometabolic Risk Factors
Table 2 provides data for cardiometabolic risk status and
treatment for the total population sample and by sex.
Body Composition
Males and females had similar mean body mass and waist
circumference; females’ mean BMI was 14% higher compared
to males’ (p = 0.03). Some participants declined body mass (n =
2) and waist circumference (n = 4) measures.
According to WHO BMI thresholds, 73% of participants were
overweight or obese. For abdominal adiposity, 9.5% of
participants met IDF criteria for elevated risk and WHO
criteria for increased risk of metabolic complications and 50%
met WHO criteria for a substantially increased risk of
metabolic complications.
Cardiometabolic Measurements
Forty-five percent had a resting pulse > 80 beats.min−1; 21% had
a resting pulse > 100 beats.min−1. Two-thirds of the cohort was
classified as pre-hypertensive (47%) or hypertensive (23%) using
WHO thresholds compared to 47% having hypertension using
IDF criteria. One participant was being treated with
antihypertensive medication; three participants declined to be
tested. No females met the WHO threshold for hypertension
whereas three females met the IDF criteria. Males had ~14%
higher systolic blood pressure (SBP) compared to females (p =
0.01); no sex differences were observed for DBP or resting pulse.
Fifty-eight percent had one or more clinical values which met
WHO and IDF criteria for lipid disturbance: hypercholesterolemia
(32%), suboptimal HDL-C levels (36%), and hypertriglyceridemia
(40%). Males and females had similar mean values for blood lipid
assessments and prevalence rates for dyslipidemia. Depending on
EIP team location, glucose metabolism was determined using either
FPG and/or HbA1c. According to IDF, 22% met the criteria forNovember 2020 | Volume 11 | Article 564240
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thresholds, 24% were identified as being at high risk for T2DM:
22% had elevated FPG, 6% had raised HbA1c and one participant
was previously diagnosed with T2DM. Ninety-six percent of
patients had at least one of the Lester UK high risk thresholds.
Four individuals declined to have blood lipid and glucose measures
assessed. Only 37 participants had prolactin measured, where four
males (15%) and six females (55%) exceeded the prolactin threshold
for hyperprolactinemia.
Across all participants, significant relationships were
observed for waist circumference and resting pulse (r = 0.37;
p = 0.02), SBP (r = 0.35; p = 0.03), diastolic blood pressure (DBP)
(r = 0.32; p = 0.04), and HDL-C (r = −0.38; p = 0.02). Resting
pulse was correlated to DBP (r = 0.510; p < 0.001) and HbA1c
(r = 0.47; p = 0.01). HbA1c also showed a medium correlation toFrontiers in Endocrinology | www.frontiersin.org 4HDL-C (r = 0.45; p = 0.01). In males, waist circumference was
positively correlated to body mass (r = 0.93, p < 0.001), resting
pulse (r = 0.39, p = 0.04), and total cholesterol (r = 0.42, p = 0.03),
and inversely correlated to HDL-C levels (r = −0.48, p = 0.01). In
females, only waist circumference and body mass had a positive
correlation (r = 0.62, p = 0.04). No other relationships were
observed between anthropometric and cardiometabolic markers
(p > 0.05).
Effect of Medications and DUP on Risk
Profile
Of the 16 individuals on high risk obesogenic medication, Clozapine
(n = 3) or Olanzapine (n = 13), 81% were overweight/obese, 56%
had elevated abdominal obesity, 38% were pre-hypertensive and
38% hypertensive according to WHO guidelines. Using IDFTABLE 2 | Cardiometabolic risk status at baseline by sex.
Variable Threshold N Total N Males N Females p Value
Age 46 24.5 (4.4) 33 24.0 (3.9) 13 25.7 (5.4) 0.252
Body Composition
Weight (kg) 44 87.8 (16.6) 32 87.4 (14.8) 12 89.6 (21.5) 0.668
BMI (kg.m2) >25.0 44 28.9 (5.8) 32 27.7 (5.0) 12 31.9 (6.9) 0.032*
Weight Status (%)
Underweight >18.5 kg.m2 44 2 (4.5%) 32 2 (6.3%) 12 0 –
Normal 18.5–24.9 kg.m2 44 10 (22.7%) 32 9 (28.1%) 12 1 (8.3%) –
Overweight 25.0–29.9 kg.m2 44 16 (36.4%) 32 11 (34.4%) 12 5 (41.7%) –
Obese 30.0–34.9 kg.m2 44 11 (25.0%) 32 9 (28.1%) 12 2 (16.7%) –
Morbidly Obese >35.0 kg.m2 44 5 (11.4%) 32 1 (3.1%) 12 4 (33.3%) –










42 4 (9.5%) 30 2 (6.6%) 12 2 (16.6%) –
WHO: Substantially increased Risk ♂ > 102 ♀ > 88 42 21 (50%) 30 12 (40.0%) 12 9 (75.0%) –
Cardiometabolic Measurements
SBP (mm Hg) 43 126.8 (19.8) 32 131.3 (20.0) 11 113.8 (12.5) 0.010*
DBP (mm Hg) 43 80.7 (16.7) 32 82.4 (17.9) 11 75.5 (11.6) 0.242
WHO Prehypertensive (%) SBP: 120–139 mmHg
DBP: 80–89 mm Hg
43 20 (46.5%) 32 12 (37.5%) 11 8 (72.7%) –
WHO Hypertension (%) >140/90 mm Hg 43 10 (23.3%) 32 10 (31.3%) 11 0 –
IDF Hypertension (%) >130/85 43 20 (46.5%) 32 17 (53.1%) 11 3 (27.3%) 0.143
Resting pulse (beats.min−1) >80 42 78.7 (17.6) 31 79.4 (18.0) 11 76.7 (16.9) 0.672
Total Cholesterol (mmol.L−1) ≥5.2 43 4.7 (1.1) 31 4.9 (1.2) 12 4.5 (0.8) 0.328
LDL Cholesterol (mmol.L−1) 18 3.0 (0.8) 13 3.0 (0.7) 5 2.8 (1.0) 0.532
HDL-C (mmol.L−1) ♂ <1.03
♀ <1.29
42 1.3 (0.3) 31 1.2 (0.3) 11 1.3 (0.4) 0.262
Triglycerides (mmol.L−1) >1.7 20 1.6 (1.0) 14 1.8 (1.1) 6 1.2 (0.7) 0.257
Dyslipidemia (%) number (%) > 1 lipid value above recommended level 43 25 (58.1%) 31 19 (61.3%) 12 6 (50.0%) –
FPG (mmol.L−1) >5.6 32 5.1 (0.8) 21 5.1 (0.9) 11 5.0 (0.5) 0.693
HbA1c (mmol.mol) >42 31 36.7 (7.8) 22 37.5 (8.9) 9 34.6 (3.4) 0.343
MetS number (%) that met IDF criteria 46 14 (30.4%) 33 11 (33.3%) 13 3 (23.1%) –
Prolactin (mIU/L−1) ♂ < 424
♀ < 530
37 501.4 (710.9) 26 295.2 (172.6) 11 988.7 (1172.0) 0.079
Health Risk Behaviors
Smoking Currently smoke or within past 3 mos. 44 24 (54.5%) 31 19 (61.3%) 13 5 (38.5%) 0.110
Alcohol Use Any alcohol use 44 17 (38.6%) 31 11 (35.5%) 13 6 (46.2%) 0.512
Substance Use Any recreational drug use 44 8 (18.2%) 31 6 (19.4%) 13 2 (15.4%) 0.758
Unhealthy eating < 5 fruits/veg.d−1 44 23 (52.3%) 31 13 (41.9%) 13 10 (76.9%) 0.036*
Sedentary Lifestyle < 90 min.wk−1 44 17 (28.6%) 31 12 (38.7%) 13 5 (38.5%) 0.988November 2020 | Volume 11 | Article*p < 0.05.
BMI, body mass index; IDF, International Diabetes Federation; WHO, World Health Organization; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure;
HDL–C, high density lipoprotein cholesterol; HbA1c, glycated haemoglobin; MetS, metabolic syndrome.564240
Smith et al. Cardiometabolic Risk in FEP Patientsguidelines, 56%were hypertensive, 69% had dyslipidaemia, and 31%
met the criteria for MetS; three participants declined blood
lipid measurements.
Twenty-nine participants had a DUP <1 month (age range
19–32 years). Even with a short DUP, 18% met WHO and 43%
met IDF criteria for high blood pressure, 32% had elevated
cholesterol, 39% had sub-optimal HDL-C, 33% had high
triglycerides, 54% met the IDF threshold for dyslipidemia,
35% met criteria for MetS, and 93% had at least one of theFrontiers in Endocrinology | www.frontiersin.org 5Lester UK high risk thresholds (see Table 3). Binary regression
analysis revealed no significant relationships (p > 0.05) where
neither antipsychotic medication or DUP nor their interaction,
were able to predict the likelihood of MetS, dyslipidemia or
hypertension in this cohort.
Health Risk Factors
Participants’ self-reported health risk behaviors including
smoking (55%), alcohol intake (39%), substance use (18%),TABLE 3 | Cardiometabolic risk status for individuals with DUP < 1 month.
Variable Threshold N Total N Males N Females p Value
Age 29 24.6 (3.9) 20 24.2 (3.6) 9 25.7 (4.6) 0.362
Body Composition
Weight (kg) 29 83.8 (14.2) 20 84.1 (14.4) 9 83.3 (14.8) 0.862
BMI (kg.m2) >25.0 29 27.8 (5.8) 20 26.7 (5.4) 9 30.1 (6.1) 0.141
Weight Status (%)
Underweight >18.5 kg.m2 29 2 (6.9%) 20 2 (10.0%) 9 0 –
Normal 18.5–24.9 kg.m2 29 8 (27.6%) 20 7 (35.0%) 9 1 (11.1%) –
Overweight 25.0–29.9 kg.m2 29 10 (34.5%) 20 5 (25.0%) 9 5 (55.6%) –
Obese 30.0–34.9 kg.m2 29 6 (20.7%) 20 5 (25.0%) 9 1 (11.1%) –
Morbidly Obese >35.0 kg.m2 29 3 (10.3%) 20 1 (5.0%) 9 2 (22.2%) –










27 3 (11.1%) 19 1 (5.3%) 8 2 (25.0%) –
WHO: Substantially increased Risk ♂ > 102 ♀ > 88 27 14 (51.9%) 19 8 (42.1%) 8 6 (75.0%) –
Cardiometabolic Measurements
SBP (mm Hg) 28 125.8 (17.6) 20 130.2 (17.6) 8 115.0 (13.0) 0.037*
DBP (mm Hg) 28 84.4 (18.6) 20 86.9 (20.8) 8 78.0 (9.7) 0.260
WHO Prehypertensive (%) SBP: 120–139 mmHg
DBP: 80–89 mm Hg
28 16 (57.1%) 20 9 (45.0%) 8 7 (87.5%) –
WHO Hypertension (%) >140/90 mm Hg 28 5 (17.9%) 20 5 (25.0%) 8 0 –
IDF Hypertension (%) >130/85 28 12 (42.9%) 20 10 (50.0%) 8 2 (25.0%) 0.328
Resting pulse (beats.min−1) >80 27 79.3 (17.8) 19 79.6 (18.4) 8 78.6 (17.4) 0.902
Total Cholesterol (mmol. L−1) ≥5.0 26 4.5 (0.9) 18 4.4 (0.9) 8 4.5 (0.8) 0.754
LDL-C (mmol. L−1) 12 2.7 (0.8) 8 2.7 (0.6) 4 2.8 (1.1) 0.821
HDL-C (mmol. L−1) ♂ < 1.03
♀ < 1.29
26 1.2 (0.3) 18 1.2 (0.3) 8 1.2 (0.3) 0.796
Triglyceride (mmol. L−1) > 1.7 12 1.7 (1.1) 8 1.8 (1.3) 4 1.3 (0.8) 0.508
Dyslipidaemia (%) number (%) > 1 lipid value above recommended level 26 14 (53.8%) 18 9 (50.0%) 8 5 (62.5%) 0.644
FPG (mmol. L−1) >5.6 20 5.0 (0.7) 12 4.9 (0.8) 8 5.1 (0.5) 0.589
HbA1c (mmol.mol) >42 (6.0%) 18 37.6 (10.0) 11 39.9 (12.3) 7 34.0 (2.6) 0.233
MetS number (%) that met IDF criteria 29 10 (34.5%) 20 7 (35.0%) 9 3 (33.1%) 0.945
Prolactin (mIU/L−1) ♂ < 424
♀ < 530
22 676.5 (883.7) 14 332.9 (218.3) 8 1277.6 (1267.0) 0.074
Health Risk Behaviors
Smoking Currently smoke or within past 6 months. 28 17 (60.7%) 19 13 (68.4%) 9 4 (44.4%) 0.174
Alcohol Use Any alcohol use 28 12 (42.9%) 19 8 (42.1%) 9 4 (44.4%) 0.909
Substance Use Any recreational drug use 28 4 (14.3%) 19 3 (15.8%) 9 1 (11.1%) 0.746
Unhealthy eating <5 fruits/veg.d−1 28 15 (53.6%) 19 8 (42.1%) 9 7 (77.8%) 0.083
Sedentary Lifestyle <90 min.wk−1 28 11 (39.3%) 19 8 (42.1%) 9 3 (33.3%) 0.663November 2020 | Volume 11 | Article 56424*p < 0.05.
BMI, body mass index; IDF, International Diabetes Federation; WHO, World Health Organization; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure;
HDL–C, high density lipoprotein cholesterol; HbA1c, glycated haemoglobin; MetS, metabolic syndrome.0
Smith et al. Cardiometabolic Risk in FEP Patientspoor diet (52%), and sedentary behavior (29%). Fifty-five
percent reported smoking within the last 3 months with
46% smoking < 10 cig.d−1. No patients reported receiving
smoking cessation support (e.g., nicotine patches) nor did
clinical notes indicate a referral for smoking cessation
support. Although non-significant, males reported higher
levels of smoking (61%) compared to females (39%). Thirty-
nine percent of participants reported regular alcohol intake
with both males (36%) and females (46%) reporting regular
alcohol use. Eighteen percent of participants reported regular
substance use; males and females reported similar levels of use
(15%–19%). Fifty-two percent of participants reported eating
five fruits/veg.d−1 with a higher proportion of males (58%)
meeting the recommended amount compared to females
(23%) (p = 0.04). Twenty-nine percent reported having a
sedentary lifestyle with males and females reporting similar
PA levels (39%).
Compared to UK age-matched peers, this cohort reported
higher prevalence for high BMI, abdominal adiposity, high blood
pressure, raised glucose, and smoking (see Table 4).
Considerably higher levels of overweight/obesity, abdominal
adiposity, and high blood pressure were reported in this cohort
compared to Correll et al. (1) and Hahn et al. (43); differences in
measuring criteria for health risk behaviors limited our ability to
compare prevalence data.DISCUSSION
The aim of this study was to present an overview of the
cardiometabolic risk profile and health risk behaviors in an
unselected, young, early psychosis cohort, within 3 months of
their psychosis onset presenting at a UK EIP service. Participants
had a high prevalence of cardiometabolic risk factors due to
elevated values for BMI, waist circumference, resting pulse, blood
pressure, and blood lipids. Unhealthy health risk behaviors,Frontiers in Endocrinology | www.frontiersin.org 6including smoking, sedentary lifestyle, and poor diet, may
contribute to an elevated risk for CVD. This is the first UK
study to demonstrate that young people with psychosis, with a
short DUP and very early in EIP treatment, are at increased risk
for cardiometabolic disorders. This data highlights the need for
physical health and health behavior interventions early in the
treatment process, particularly for individuals taking the most
obesogenic medications, to address the increased risk for
cardiometabolic disorders in individuals recently diagnosed
with psychosis.
Prevalence of Cardiometabolic Risk
Markers
Compared to UK age-matched individuals and previous
published research, this cohort had a higher prevalence of
overweight/obesity, abdominal adiposity, hypertension, and
elevated lipid measures (1, 3, 30, 43, 44). Despite a short DUP
of less than 3 months since their psychosis onset and having a
physical health assessment within 6 weeks of being taken on to
EIP caseload, 93% met at least one of the Lester UK Adaptation
“Red Zone” threshold criteria (37). This may, in part, be due to
the high number (35%) of individuals prescribed high risk
obesogenic antipsychotic medications. Females appeared at
particular risk for obesity and increased abdominal obesity
which may relate to the self-reported unhealthy eating,
sedentary lifestyle, and antipsychotic medication prescribing.
Individuals in this younger age group are not typically
considered at risk for MetS; however, 58% had dyslipidemia,
40% had hypertriglyceridemia, and 30% of participants met the
IDF MetS criteria. High triglycerides, typically elevated in FEP,
are a precursor for T2DM (31). The MetS prevalence in this
cohort compares favourably to the elevated risk for MetS
described for people with schizophrenia and related psychotic
disorders identified in Vancampfort et al.’s (45) meta-analysis.
Vancampfort et al. (45) reported the weighted estimated mean
prevalence of MetS in population-based studies was 32.6%; 1.58TABLE 4 | Comparison of cardiometabolic risk factor prevalence to age-matched peers.
Variable This study (UK) UK age-matched general population average (2015)a Correll et al. (1)b (USA) Hahn et al., (43)c (Australia)
Age (years) 16–34 16–24 25–34 15–40 18–24
Overweight/Obese 72.8% 38.8% 52.3% 48.3% 55.0%
Abdominal Adiposity 50.0% 20% 28% 17.5% –
Pre-hypertensived 46.5% – – 39.9% –
Hypertensiond 23.3% 3.2% 6.3% 10.0% 8.0%
High Total Cholesterol 40.0% – 15.4% 12.6%
Dyslipidaemia 58.1% – 56.5% –
Elevated FPG 21.9% – – 6.9% 16.1%
Elevated HbA1c 6.4% 0.6% 0.8% – 12.9%
MetS 30.4% – 13.2% –
Smoking 54.6% 24% 24% 50.8% 67.7%
Alcohol Use 38.6% 50% 58% – 8.2%
Substance Use 18.2% 18% – –
Unhealthy Eating 52.3% 72% 74% – 77.9%
Sedentary Lifestyle 38.6% – – – 41.2%November 2020a(43). High blood glucose = doctor diagnosed diabetes.
b(1). Abdominal adiposity = waist circumference > 102 cm for males and females.
c(42). Unhealthy eating = < 4 fruit and vegetable per day. Alcohol = > 4 drinks per day, 4 or more times per week. Sedentary lifestyle = < 2.5 hr.wk
−1 of moderate or < 1 hr.wk−1 of vigorous exercise.
d(35). Blood pressure classifications were based on WHO guidelines.| Volume 11 | Article 564240
Smith et al. Cardiometabolic Risk in FEP Patientstimes higher risk than the general population. In young people
with SMI, weight gain is exacerbated as they are more likely to
engage in unhealthy health risk behaviors (46–48). It is
particularly during adolescence when there is the greatest
likelihood of excessive weight gain (>45 pounds) where the
prevalence of obesity doubles between pre-adolescence (~17%)
and young adulthood (~34%) (49).
Individuals prescribed obesogenic antipsychotic medications
are at even greater risk for obesity and obesity related disorders
(50). However, there is preliminary evidence that metabolic
disturbances may begin early even prior to starting medication
(3). Mitchell et al.’s (3) meta-analysis of unmedicated and first
episode schizophrenia patients found an overall rate of MetS of
approximately 10% where the metabolic risk in FEP was not
significantly increased compared to unmedicated patients.
However, this finding may be explained by the inclusion of only a
limited number of first episode patients who had been exposed to
antipsychotic medication (5 out of 26 FEP studies) and where
antipsychotic exposure, in 3 of those 5 studies, was very short from
less than 2weeks to less than 3months. Given our sample were also
young and within 3 months of their psychosis onset, based on this
meta-analysis, we should have expected a lower cardiometabolic
risk in our cohort offirst episode early psychosis patients. However,
even though individuals were picked up very quickly following
psychosis onset and our clinical assessments took place within 6
weeks of acceptance onto an EIP caseload, themajority (80%) were
already in receipt of and established on antipsychotic medication.
Information about dosage and length of exposure to antipsychotic
medication were not collected in this study. This may limit our
findings as these are potential confounding factors which may
influence the degree of cardiometabolic risk observed in
these participants.
This is one of the first UK papers which has identified that
clinical markers of MetS were most evident in those treated
promptly with antipsychotic medications based on DUP (<1
month). Excess abdominal adiposity in this cohort was correlated
to elevated resting pulse, SBP, DBP, and lower HDL-C levels
increasing the risk for metabolic and cardiovascular disorders,
particularly MetS, earlier in the life course. Longer term physical
health outcomes need to be considered alongside mental health
outcomes where currently prompt antipsychotic treatment may be
at the expense of physical health morbidity and mortality.
Health Risk Behaviors Contributing to
Increased Risk
Across theUK, smoking and alcohol use has been steadily declining
(51, 52). The smoking prevalence in this sample (55%) is similar to
comparable SMI populations (50%–68%) (1, 43, 53) and the 47%
smoking rate observed in FEP patients in the Mitchell et al.’s (3)
meta-analysis, but is considerably lower than the more recent,
Gaughran et al. (30) and Lally et al. (53) studies which identified
much higher rates of cigarette smoking (76.8% and 78%
respectively) in FEP patients. These continued higher rates of
smoking in FEP are noteworthy when compared to rates of 19%–
21% in the age-matched general population where we have seen
significant reductions in cigarette use across theUK (51). Substance
and alcohol use were at or below national averages for UKFrontiers in Endocrinology | www.frontiersin.org 7age-matched adults (18% and 81%, respectively) (44, 52).
Previous research has argued nicotine, alcohol, and substance use
may be used to self-medicate to alleviate psychiatric symptoms (e.g.
side effects, cognitive deficits) by increasing dopamine levels (47,
54).Manzella et al. (55) suggested there is a lack of data to support a
self-medication hypothesis to explain high smoking prevalence in
this population. Elevated rates of addictive substances may also be
due to habit, routine, social contact, relaxation, and as a control
mechanism (56, 57). As smoking has been shown to double the risk
ofmorbidity andmortality (58), and is one of the largest potentially
modifiable risk factors that is present soon after diagnosis, it is an
important early target for cardiometabolic risk prevention and, as
such, evidence based smoking cessation programs should be
prioritized (59, 60). At the time of study, no pathway to refer for
smoking cessation support was available in either primary or
secondary care locally which may explain the absence of evidence
in clinical notes of patients receiving nicotine patches or onward
referral to smoking cessation services. Although even if a pathway
had been available, people with SMI have not historically
successfully engaged with generic smoking cessation services (60).
The recent SCIMITAR+ study (60) successfully trained mental
health practitioners to deliver a bespoke behavioral (evidence-
supported techniques to change smoking behavior) combined
with pharmacological smoking cessation interventions to an older
group of patients with SMI (mean age 47 years).The SCIMITAR+
intervention increased engagement and chances of successful
quitting at 6 months, which were more than twice the rates of
those who received usual care, although these differences were not
significant by 12 months. Long-term smoking cessation remains
difficult to achieve and is a continuing challenge for nicotine
dependence in any population, not just psychosis (60). Further
research is needed to examine whether the SCIMITAR+
intervention could be adapted to be delivered in EIP services with
first episode patients where smoking habits and nicotine
dependence may be less strongly established and, potentially, its
impact might be greater (61, 62).
Meaningful comparisons of PA and unhealthy eating were
difficult as previous studies used different criteria (i.e., PA <
150 min.wk−1 and diet > 4 fruit/veg.d−1 (1, 43). High body mass
and abdominal obesity are consistent with poor dietary habits and
lower levels of PA. Although there are validity concerns about self-
reported behavioral data (63), self-reported assessments of diet (64,
65), PA, and substance use are accepted methods to identify
potential population health risks and conform to NICE Psychosis
and Schizophrenia Clinical Guidelines CG178 (66) and NICE
Psychosis and Schizophrenia Quality standards (QS80) (67) for
health risk behaviors data collection. The use of more reliable and
valid objective measures of health risk behaviors would enhance
rigor, data confidence and comparability between studies but may
not be practical, affordable, or even achievable in a busy, routine
clinical service setting. Furthermore, this may inhibit successful
screening if measures such as wearing an accelerometer or blood/
urine tests are viewed as intrusive and unacceptable to this
population given in this study, less than half of participants
agreed to complete blood profile assessments and several refused
intimate measures which fitting monitoring equipment, such as an
accelerometer for measuring PA, would necessarily entail.November 2020 | Volume 11 | Article 564240
Smith et al. Cardiometabolic Risk in FEP PatientsNotwithstanding these potential measurement limitations, these
combined health risk factors contribute to elevated CVD risk
markers in young people with psychosis providing a rationale for
health behavior intervention to systematically address unhealthy
health risk behaviors.
Evaluation of Clinical Service
This evaluation identified a number of physical health screening
challenges. A key finding was inconsistent screening of physical
health risk factors and inadequate recording in the clinical notes
of subsequent referrals for monitoring and intervention of
patients identified as being at risk. Patient challenges to
obtaining complete health assessment data included refusal to
give blood, refusal of taking intimate measures (i.e., waist
circumference, bloods) on religious grounds, and non-
attendees. UK standards require completion of all seven
clinical markers to meet national EIP audit criterion (CQUIN
2015–2017) (68) which are limited by these patient challenges.
Elevated values for clinical markers were not supported with
documented evidence of specialist referral. Referral for specialist
diabetes support was hampered by the absence of clear, referral
pathways directly from mental health services and instead, relied
on general practitioner referral when patients were identified as
at risk and flagged up for specialist assessment and intervention.
No pathway to refer for generic smoking cessation support was
available in either primary or secondary care locally which meant
patients who expressed a desire to stop smoking were unable to
be referred to this intervention. Clearer referral pathways for
patients identified as being at risk may improve access to
specialist assessment and intervention in response to screening.
However, progress and outcomes of referrals made need to be
monitored and incorporated into routine care planning review
processes to ensure a successful intervention response when risks
are identified. It was also challenging to make meaningful
comparisons with international parameters (IDF, WHO, Lester
UK Adaptation) as threshold criteria varied according to the
comparator employed and inconsistency in data sets for age-
matched populations. Standardisation of clinical assessment
forms and measurement consensus for clinical markers across
EIP teams may improve consistency of screening recording, and
timely referrals for intervention.CONCLUSION
On presentation to an EIP service, young people with FEP are at
increased risk for cardiometabolic disorders due to elevated clinical
risk markers and adverse health risk behaviors. Physical healthFrontiers in Endocrinology | www.frontiersin.org 8monitoring and targeted health behavior interventions, including
bespoke smoking cessation, are needed early in the treatment
process to attenuate identified risk markers for chronic disease
and premature mortality. Streamlined processes are needed to
ensure consistency in EIP service delivery and improve screening,
referral and intervention processes.DATA AVAILABILITY STATEMENT
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